Ann Surg Oncol (2018) 25:1828–1835 https://doi.org/10.1245/s10434-018-6361-5 O R I G IN AL ARTI CL E – MELA NO MA S 1 2 3 4 Frances Collichio, MD , Lauren Burke, MD , Amber Proctor, Pharm D , Diana Wallack, BS , 5 6 6 Anthony Collichio, BSc , Patricia K. Long, MSN, FNP-C , and David W. Ollila, MD Division of Hematology-Oncology, Department of Medicine, The University of North Carolina, Chapel Hill, NC; 2 3 Department of Radiology, The University of North Carolina, Chapel Hill, NC; Department of Pharmacy, The University 4 5 of North Carolina, Chapel Hill, NC; The Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Boston University, Boston, MA; Division of Surgical Oncology, The University of North Carolina, Chapel Hill, NC ABSTRACT quality of treatment for patients who suffer from advanced Background. Oncolytic viruses are genetically engineered melanoma. or naturally occurring viruses that selectively replicate in cancer cells without harming normal cells. Talimogene laherparepvec (Imlygic ), the ﬁrst oncolytic viral therapy BACKGROUND approved for treatment of cancer, was approved for treat- ment of locally advanced melanoma in October 2015. Oncolytic viruses are designed to replicate uncontrol- Purpose. As a biologic product, use of T. laherparepvec in lably
Annals of Surgical Oncology – Springer Journals
Published: Feb 7, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud